CAPA serves as the engine of a high-performance Pharmaceutical Quality System (PQS). It shifts quality management from reactive "firefighting" to a results-oriented strategy that optimizes processes across manufacturing and the global supply chain. Authorities such as the FDA, WHO, EMA, and CDSCO require a robust CAPA system. During GMP inspections, your CAPA records tell the story of your quality culture and your commitment to operational excellence.

This June 2026 notification signals a maturing pharmacovigilance framework. For stakeholders from large-scale manufacturers and CMOs to frontline healthcare providers, the message is clear: scientific justification is the only path to market survival. This article breaks down the ban and explores the strategic shifts necessary for industry compliance.

Pharmaceutical manufacturing serves as the vital backbone of healthcare systems worldwide. It is the engine that ensures that safe, effective, and high-quality medicines are consistently produced and delivered to patients across diverse geographies, socioeconomic strata, and clinical needs.

Key global regulators such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO) are constantly updating their rules. This is a direct response to the increasing complexity of new therapies and global supply chains. Their goal is to ensure innovation never comes at the cost of patient safety or product quality.

Geopolitical tremors are no longer confined to distant maps, they are systemic shocks that hit close to home, impacting the cost and availability of essential goods. The escalating Iran-Israel conflict is a perfect example. What begins as a regional confrontation has swiftly become a global economic disruptor, with immediate and profound consequences for the healthcare industry.

The blog is the final segment of our nutraceutical playbook, highlighting brand building in Nutraceuticals, role of CDMOs in brand success, and why choose Walter as your partner.

This blog is the highlight of the changing healthcare landscape from the clinical system to the preventive one. A cornerstone of this modern movement is the ascending role of nutraceuticals. These are not just simple supplements; they are scientifically engineered nutritional products specifically designed to bolster overall health, enhance the body's natural resilience, and maintain internal balance before the onset of disease. Consequently, nutraceuticals are evolving fro

The blog is a highlight of the new economic game-changer agreement. This FTA between India and New Zealand, as a significant step in this direction was the successful conclusion of negotiations for a comprehensive Free Trade Agreement (FTA) between India and New Zealand on December 22, 2025. This pact is notable for its speed, negotiated in less than a year, and marks the seventh major trade agreement for India in the last five years.

It provides essential coverage for a wide range of conditions, from respiratory and skin infections to various mixed bacterial ailments across all age groups, particularly when single-agent antibiotics fail. The power of this formulation lies in its strategic, dual-action mechanism. Amoxycillin offers potent, broad-spectrum bactericidal activity. Simultaneously, Clavulanic Acid acts as a guardian, breaking down the resistance mechanisms that bacteria use to neutralize the a

This blog explores how the fixed-dose combination of Pantoprazole 40 mg + Domperidone 10 mg delivers a dual-action advantage in GERD and acid-related disorders. By combining Pantoprazole’s powerful acid suppression with Domperidone’s prokinetic action, it ensures faster relief, improved gastric motility, and long-lasting patient comfort. The article highlights its clinical superiority over monotherapy, regulatory acceptance, and formulation excellence by Walter Healthcare, ma

The India-UK Free Trade Agreement unlocks zero-duty access and faster approvals for Indian pharma exports, paving the way for deeper...